ROS1-Rearranged NSCLC 
Chromosomal rearrangements of the gene encoding ROS1 have been found in approximately 1% of patients with NSCLC [63]. Due to considerable homology between the kinase domains of ROS1 and ALK, drugs used to treat ALK-positive tumors including crizotinib[63], ceritinib [64] and lorlatinib [65] have also shown marked activity in ROS1-positive tumors. Crizotinib was found to have a response rate of 72% and median PFS of 19 months in 50 patients with NSCLC and ROS1 rearrangement [63]. Repotrectinib (TPX-0005) may be an effective therapeutic option for patients with NTRK1–3, ROS1 or ALK-rearranged advanced NSCLC who have progressed on earlier-generation TKIs as it is known to overcome resistance due to acquired mutations involving NTRK 1-3, ROS1 and ALK [66].Cabozantinib has also demonstrated anti-ROS1 activity in the second-line setting, including activity against G2032R.Most agents demonstrated good tolerability, with safety and efficacy data that are being confirmed in ongoing clinical trials, except cabozantinib which isassociated with higher toxicity, and it is therefore limited as a therapeutic agent for some patients.